Treatment Action Group (TAG) welcomes the exciting news of a novel tuberculosis (TB) drug entering priority review by the Food and Drug Administration (FDA). Pretomanid represents only the fourth new TB drug to go through stringent regulatory review in the past half a century, and the first developed by a not-for-profit organization.
In our two briefs, Closing the Gap in Tuberculosis Research and Development Funding: Actions for U.S. Government Executive Agencies and Actions for U.S. Congress, we detail how a funding increase of 0.1 percent, based on "fair share" of research capacity, would close the funding gap in TB R&D, catalyze new public health tools we need to create positive health outcomes among communities vulnerable to TB worldwide.
TAG recently submitted a public comment to the National Institute on Drug Abuse (NIDA) at the National Institute of Health to inform a strategic plan it is developing to support research at the intersection of HIV and drug use.
Good COPs or Bad COPs 2.0: Advocacy to Ensure the Prioritization of TB in 2019 PEPFAR Country Operational Plans (COPs) Every year, PEPFAR meets to discuss their strategy and budget for the following year, and set targets on implementing country operation plans…
TAG recently submitted this public comment on Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions, highlighting the need to mitigate national supply challenges and shortages of critical TB drugs.
On January 11, 2019, TB Project Co-Director Lindsay McKenna attended a half-day conference hosted by the NYC Bureau of Tuberculosis Control. The recommendations from the conference are included in the NYC Department of Health and Mental Hygiene’s press release on the event, which you can download below.
by Mike Frick and Lindsay McKenna, TB Project Co-Directors, TAG In an interview with TAG’s Tuberculosis (TB) Project, Marc Destito, Senior Director of Public Affairs and Global Alliance Management at Otsuka Pharmaceutical, provides insight into how the development of TB…
By Bryn Gay, HCV Project Director, TAG and Claudine Guerra, CUNY DOWNLOAD to print this article as a poster (A1 size) The current leaders of the United States manufacture crises, media optics, and catchy sound bites to side step actual…
By Annette Gaudino, HCV/HIV Project Co-Director, TAG Do you remember how old you were when you stopped believing in the monster under your bed? How many times did you have to look and see nothing there before you finally believed…
By Bryn Gay, HCV Project Director, TAG Access to medicines (A2M) activists have become better coordinated, articulate, and adept in responding to pharmaceutical industry shenanigans that threaten access to affordable medicines since the establishment of harmonized global intellectual property (IP) …